nach oben

Erschienen in:

Open Access 01.12.2001 | Review

Interactions between genes and environmental factors in asthma and atopy: new developments

verfasst von: Claudia Sengler, Susanne Lau, Ulrich Wahn, Renate Nickel

Erschienen in: Respiratory Research | Ausgabe 1/2002

Abstract

Asthma and associated phenotypes are complex traits most probably caused by an interaction of multiple disease susceptibility genes and environmental factors. Major achievements have occurred in identifying chromosomal regions and polymorphisms in candidate genes linked to or associated with asthma, atopic dermatitis, IgE levels and response to asthma therapy. The aims of this review are to explain the methodology of genetic studies of multifactorial diseases, to summarize chromosomal regions and polymorphisms in candidate genes linked to or associated with asthma and associated traits, to list genetic alterations that may alter response to asthma therapy, and to outline genetic factors that may render individuals more susceptible to asthma and atopy due to environmental changes.

β₂AR

beta-2 adrenergic receptor

atopic dermatitis

interleukin

5-LO

5-lipoxygenase

SNP

single nucleotide polymorphism

TDT

transmission disequilibrium test.

Introduction

The prevalence of asthma, allergic rhinitis and atopic dermatitis (AD) has dramatically increased over the past decades. These atopy-related diseases are the most common chronic disorders in childhood in Western societies. Several epidemiological studies have evaluated environmental risk factors that may explain the steady increase of allergic disease. (Note: in this article, allergic diseases/atopic disorders include asthma, allergic rhinitis and AD. Atopy-associated phenotypes/traits include, in addition, allergic sensitization, elevated total serum IgE and eosinophilia.) There is growing evidence that contact to bacterial antigens (such as endotoxin) and viral infections in early childhood is protective with regard to development of allergic disease in later life [1,2,3,4,5,6]. Although changes in lifestyle significantly contribute to disease expression, heritability has been shown to play a major role in the pathogenesis of allergic disease.

Multiple twin and family analyses strongly imply a genetic basis for atopy-related traits (for a review, see [7]). A recent study of 11,688 Danish twin pairs (comparing identical and non-identical twin pairs) suggested that 73% of asthma susceptibility is due to genetic factors [8]. However, atopy-associated phenotypes, including asthma, do not appear to follow any Mendelian inheritance pattern, which is characteristic for complex genetic (multifactorial) traits. The dissection of these traits is hampered by phenocopy, incomplete penetrance, and genetic heterogeneity [9]. The complexity of the genetics of asthma and other atopy-associated phenotypes is reflected by an increasingly large number of chromosomal regions showing (weak to moderate as defined in [9]) evidence for linkage, as well as various genetic variations in multiple candidate genes that are associated with asthma and associated phenotypes.

Methodology in genetic studies of complex traits

Microsatellite marker analysis

The majority of studies on genetics of complex traits to date have been based on microsatellite marker (synonym, short tandem repeat polymorphisms [STRP]) analyses. These genetic markers (whose biological function is as yet unknown) typically contain a variable number of tandem repeats of dinucleotide, trinucleotide or tetranucleotide DNA sequences (e.g. the tetranucleotide [TATA]_n). The high degree of polymorphism results in great variation between individuals. Short tandem repeat polymorphisms of known location are found densely spaced throughout the genome and are used for genome-wide searches as well as for the analysis of candidate gene regions.

Study designs in analyses of complex genetic traits

Most studies on the genetics of asthma are based on allele sharing methods, transmission disequilibrium test (TDT) analysis, or tests for associations. The allele sharing methods approach involves testing how often a genetic marker (or a chromosomal region) is shared by affected pedigree members. If allele sharing occurs significantly more often than expected by chance, linkage of the particular marker and disease can be assumed, indicating that the chromosomal region containing the genetic marker also contains a gene that contributes to disease expression.

The TDT approach is based on genotype analysis of affected subjects (no siblings are required) and their parents. The TDT tests whether genetic marker alleles from heterozygous parents are transmitted as frequently as expected by chance (by random, each parental allele is transmitted with a chance of 50%). Overtransmission of a particular marker allele indicates linkage of this allele with the respective 'disease' allele.

Association studies are usually applied once polymorphisms in candidate genes for asthma/atopy have been identified.

Linkage and candidate gene studies in asthma and atopy

Linkage studies

Results from linkage studies (genome-wide searches and candidate gene region analyses) are summarized in Supplementary Tables 1 and 2 (see also [10,11,12,13]). Multiple chromosomal regions were related to asthma and atopy. Few regions, however, have shown evidence for linkage in more than one population (Supplementary Table 2), which may be due to racial differences, to different definition of phenotypes, or (most probably) to insufficient numbers of affected sib-pairs in different study populations. The first successful attempts have been made to pool data from genetic studies of asthma and atopy in order to analyze major candidate gene regions [14,15].

Supplementary Table 1

Results of genome-wide searches (asthma and associated traits)

	Study
				Hizawa		Daniels	Ober	Ober	Wjst	Yokouchi		Lee	Cookson
		CSGA 1		et al.		et al.	et al.	et al.	et al.	et al.	EGEA	et al.	et al.
		(1997)		(1998)		(1996)	(1998)	(2000)^†	(1999)	(2000)	(2000)	(2000)	(2001)
						C	C	C	C (German/	C	C	C	C
Population	AA	C	H	AA	C	(Australian)	(Hutterites)	(Hutterites)	Swedish)	Japanese	(French)	(German)	(British)
Individuals (n)	117^‡	215^‡	48^‡	281	299	364	371/292	693	415	196	493	839
Sib-pairs (n)	ns	ns	ns	ns	ns	172	ns	ns	156	65	ns	199	213
1q21													AD^*
1p31											Asthma ^*
2pter									Asthma^, IgE^*
									BHR^, RAST^*
2q22-33			Asthma^*		IgE^*
3q21												AD^***
4q35						BHR^*, atopy^				Asthma^**
5p13-15	Asthma^**							BHR
								(D5S1470)
5q23-33				IgE^*			BHR^**	BHR		Asthma^***
								(D5S1462)
6p21.3-23					IgE^*	Eos^***			Asthma^, IgE^
									RAST^*
7p						IgE^, BHR^*
						(D7S2250, D7S484)
8p23.3				IgE^*				Asthma
								(D8S1136)
9 (DS1784)									Asthma^, IgE^
									RAST^*
11p13-15		Asthma^*									IgE^*
11q13						IgE^, ST^*					IgE^*
12q13-24.2		Asthma^*					BHR^*		Asthma^*		Eos^**
13q11-32.2		Asthma^*			IgE^*	Atopy^**				Asthma^**	Eos^*
14q11.2-13		Asthma^*
14q32								BHR
								(gata193a07)
16q-tel													IgE^**
16q23-24						IgE^**		ST (D16S539)
17p11.1-q11.2	Asthma^*
17q12-21											Asthma/ST^*
17q25													AD^**
19q13		Asthma^*					Asthma^*	BHR			BHR^*
								(D19S900)
20p													Asthma^**
21q21			Asthma^*

AA, African American; AD, Atopic dermatitis; BHR, bronchial hyperresponsiveness; C, Caucasian; eos, eosinophil count; H, Hispanic; ns, not specified; RAST, radio allergo sorbent test; ST, positive skin test. ^*P ≤ 0.01, ^**P ≤ 0.001, ^***P ≤ 0.0001. ^† Statistical significance (P ≤ 0.05) in both tests, likelihood ratio Χ² test and transmission disequilibrium test. ^‡ Only affected individuals, neither number of all individuals nor number of sib-pairs specified [17,18,38,S1,S2,S3,S4,S5,S6,S7].

Supplementary Table 2

Chromosomal regions showing evidence for linkage to asthma and related phenotypes

Chromosomal region	Phenotype (linkage)	Population	Reference
5q23-33	Total IgE	Dutch, Amish, Caucasian (UK)	[S8,S9,S10]
	Total IgE, specific IgE, eosinophil count	Australian	[S11]
	Specific IgE	African American	[S12]^*
	Atopic dermatitis	Caucasian (UK), German/Swedish	[S13,S14]
	Asthma/atopy	Japanese	[S6,S15]^*
	Eosinophil count	Caucasian (US)	[S16]
	Hypereosinophilia	Caucasian (US)	[S17]
	Bronchial hyperresponsiveness	Dutch, Hutterites	[S3,S18]^*
6p21-23	Specific IgE	Caucasian (US)	[S1,S19]
	Asthma, IgE	German/Swedish	[S5]^*
	Allergic asthma	Colombian	[S20]
	Eosinophil count	Caucasian (Australian)	[S2]^*
11q13	IgE	Caucasian (UK)	[S21,S22]
	IgE, positive skin test	Caucasian (Australian)	[S2]^*
	Specific IgE	Caucasian (Australian), African American	[S11,S12]
	Bronchial hyperresponsiveness, log IgE	Caucasian (UK)	[S10]
	Bronchial hyperresponsiveness	Caucasian	[S23]
	Atopy	Japanese	[S24]
	Asthma, atopy	Caucasian	[S25]
	Atopic dermatitis	German	[S26]
12q14-24	Asthma	German/Swedish Caucasian (US)	[38,S27]^*
		Caucasian (UK)	[S28]
	Asthma, atopy	Afro-Caribbean	[S29]
	Total IgE, asthma	Afro-Caribbean, Amish	[S30]
	Total IgE	German	[S31]
	Bronchial hyperresponsiveness	Hutterites	[S3]^*
	Eosinophil count	French	[S7]^*
13q11-32	Atopic dermatitis	German/Swedish	[S14]
	Specific IgE	Caucasian (UK)	[S1]^*
	Atopy	Caucasian (Australian)	[S2]^*
	Eosinophil count	French	[S7]^*
	Asthma	Caucasian (US), Japanese	[38^,S6^]
	Atopic asthma	Japanese	[S32]

^*Genome-wide searches.

Despite the high degree of inconsistent findings, it is intriguing that chromosomal regions linked to asthma have also shown evidence for linkage to other inflammatory and autoimmune diseases (such as psoriasis, inflammatory bowel disease, type I diabetes and multiple sclerosis). Becker et al. noted that susceptibility genes for various autoimmune and inflammatory diseases (including asthma) appear to cluster in 18 distinct chromosomal regions, implying common genetic elements in inflammatory disorders [16]. This speculation is further supported by two recent genome-wide searches for AD susceptibility genes. Regions linked to AD (Supplementary Table 1) have also been linked to psoriasis in other studies [17,18], suggesting that common genetic elements are involved in dermal inflammatory disorders.

Candidate gene studies

Multiple genes are involved in the allergic inflammation (shown in Supplementary Figure 1). Multiple single nucleotide polymorphisms (SNPs) in candidate genes for asthma and atopy have been identified, and they are presented in Supplementary Table 3. The (often conflicting) results have to be interpreted with caution, since multiple genotypes are commonly tested for a large number of atopy-related (sub)phenotypes (using various statistical approaches) in often considerably small sample sizes. Therefore, type 1 errors (false-positive results) are likely to occur. In addition, publication favors positive results and, therefore, many negative studies have not been published.

Supplementary Table 3

Polymorphisms/mutations in candidate genes for asthma and related phenotypes

Chromosomal				Single nucleotide	Phenotype		Functional
location	Number^*	Molecule		polymorphism/mutation^†	related	Population	(in vitro)	Reference
1p32	1	Histamine-N-		C314T (Thr105Ile)	Asthma	Caucasian	Yes	[28]
		methyl-transferase
2q33-34	2	CD28		T19int3C	None	Caucasian		[S33]
		CTLA-4		A49G	None	Caucasian		[S33]
				C-318T	None	Caucasian
3p21	3	CCR5		CC5-Δ32	Asthma	Caucasian	Yes	[40]
					No Association	British/Australian		[41]
5q31-34	4	IL-4		C-590T	Total IgE	Japanese	Yes	[S34]
				(= C-589T)	Total IgE	American		[S35]
					Specific IgE, wheeze	Australian		[S36]
					FEV1	Caucasian		[S37]
					Atopic dermatitis	Japanese		[S38]
					None	Caucasian		[S39]
				C+33T	Total IgE	Japanese		[S40]
	5	IL-5		None		Australian		[S41]
	6	IL-13		C-1055T	Allergic asthma	Dutch		[S42]
			identical
				C-1112T	Total IgE	American/German		[19]
				A-1512C
				C1923T
				G2525A
				C2580A
				C2749T
				Arg130Gln
			identical	G4257A	High IgE, atopic dermatitis	German		[S43]
				Gln110Arg	Atopic and intrinsic	British/Japanese		[S44]
					asthma
	7	β₂-AR		G-1023A
				C-709A
				G-654A
				C-468G
				C-406T
				T-367C	Drug response	Caucasian/African American	Yes	[24]
				T-47C	(Haplotype studies)	Asian/Hispanic-Latino
				T-20C
				G46A (= Gly16Arg)
				C79G (= Gln27Glu)
				G252A
				C491T (= Thr164Ile)
				C523A
				Gly16Arg	Drug response	American	Yes	[27]
					FEV1 and FVC	Hutterites		[S45]
					Asthma severity	Not specified		[S46]
				Gly16Arg	Nocturnal asthma	American		[25]
					Steroid-dependent asthma	American		[S47]
					None	German		[S48]
					Drug response	Not specified		[S49]
				Gln27Glu	Drug response	American	Yes	[27]
					Drug response	Not specified		[S49]
					None	German		[S48]
					Total IgE	Caucasian		[S50]
					FEV1	British		[S51]
	8	IRF-1		-300 G/T	None	Japanese		[S52]
				4396 A/G	None
				6355 G/A	None
	9	CD14		-159 C → T	Total IgE	Caucasian		[S53]
					None	Hispanic		[S53]
					Total IgE	British		[S54]
					None	Japanese		[S54]
5q35	10	LTC4 synthase		-444 C	Aspirin-induced asthma	Caucasian	Yes	[30]
					None	American	No	[S55]
6p21	11	HLA-II			Specific IgE	Multiple		[S56]
		TNF		-308 TNF2	BHR	Caucasian		[S57]
		LT-α		LT alpha NcoI^*1/	Asthma	British		[S58]
				TNF-308^*2 haplotype
				-308 TNF1	Asthma	Australian		[S59]
				LT-alpha^*2	Asthma
6p21-12	24	PAF-acetyl-hydrolase		Ile198Thr	Atopic Asthma/	German/British	Yes	[S60]
					total IgE
				Ala379Val	Asthma/specific IgE		Yes
				Arg92His	None		Yes
10	12	5-LO (promoter)		(GGGCGG)_{n = 3–6}	Drug Response	Not specified	Yes	[29]
11q12-13	14	CC16		A38G	Asthma	Australian		[S61]
					None	British/Japanese		[S62]
	15	FcεR1-β		lle181Leu	Atopy	British	No	[S63]
						Japanese		[S64]
				Leu181/Leu183	Atopy, BHR	British/Australian	No	[S65]
					None	Australian		[S51]
				E237G (= Gly237Glu)	Atopy	Australian	No	[S66]
					None	Japanese		[S67]
				RsaI_in2^*B	Asthma	Australian		[S68]
				RsaI_ex7 (+ RsaI_in2^*B)	Total IgE, atopic	Not specified		[S69]
					dermatitis, asthma
				-109C/T	Total IgE	Japanese		[S70]
	13	GSTP1		Ile105Val	IgE/Skin Test/FEV1	Caucasian		[S71]
12q13	17	STAT6		G2964A	Asthma	Japanese		[S72]
12q14	16	IFN-γ		None		Australian/Venezuelan		[S73]
12q24	18	NO-synthase 1		(AAT)_{n ≥ 12}	Exhaled NO	Mixed		[S74]
14p11	19	TCR		VA8.1(^*)2	Specific IgE	Caucasian		[S75]
	20	Mast cell chymase		MCC BstXI	Eczema	Japanese		[S76]
					Total IgE	Not specified		[S77]
					None	Japanese		[S78]
					None	Italian		[S79]
					Atopic dermatitis	Japanese		[S80]
					With high IgE
16p12-p11	21	IL-4Rα		Q576R (= Arg551Gln)	Atopy, high IgE	American	Yes	[S81]
					Asthma severity (FEV1)	American		[S82]
					None	Italian		[S83]
					Atopic dermatitis	Japanese		[S84]
					Low IgE	German	Yes	[20]
				S503P (= 478Pro)	Low IgE			[20]
				E400A	None
				C431R	None
				Ile50Val	IgE/atopic asthma	Japanese	Yes	[S85]
					None	Japanese		[S86]
				Ile50Val
				Ser727Ala
				Glu375Ala
				Cys406Arg	Atopy/asthma	Hutterites/Caucasian		[21]
				Ser411Leu	(Haplotype studies)	African American/Hispanic
				Ser761Pro
				Ser478Pro
				Gln551Arg
17q11-q12	22	RANTES		G-401A	Atopic dermatitis	Caucasian	Yes	[43]
			identical
				G-403A	Asthma, atopy	Caucasian		[44]
Xq	23	IL-13Rα1		A1398G	Total IgE	British		[S44]

Divergent positions of identical mutations are due to different database accession numbers used for reference. ^* Numbers refer to molecules in Supplementary Figure 1. ^† Nomenclature as in references. β₂-AR, β₂ adrenergic receptor; BHR, bronchial hyperresponsiveness; CC16, Clara cell protein 16; CCR5, CC chemokine receptor 5; CD, cluster of differentiation; FcεR1-β, Fc epsilon receptor 1 beta (IgE receptor); FVC, forced vital capacity; FEV1, forced expiratory volume in 1 s; GSTP1, glutathione-S-transferase 1; HLA, human leukocyte antigen; IFN, interferon; IL, interleukin; IL-4/13 R, interleukin 4/13 receptor; IRF-1, interferon regulatory factor 1; 5-LO, 5-lipoxygenase; LT, leukotriene; LT-α, lymphotoxin α; LTC4, leukotriene C4 synthase; NO, nitric oxide; PAF, platelet activating factor; RANTES, regulated on activation, normal T cell expressed and secreted; STAT6, signal transducer and activator of transcription 6; TCR, T-cell receptor; TNF, tumor necrosis factor.

Functional studies

Many SNPs listed in Supplementary Table 3 have been tested for functional differences in vitro. However, when several (potentially) functional SNPs are expressed in one (regulatory region of a) gene (e.g. IL-4Rα, IL-13, beta-2 adrenergic receptor [β₂AR]), they are likely to interact. The individual analysis of SNPs may therefore not reflect in vivo gene function, as a recent study on β₂AR haplotypes demonstrated (see 'β₂-agonists' subsection). (Note: a haplotype is a particular combination of alleles in a defined region of a chromosome. It is used to describe combinations of polymorphisms in a gene/chromosomal area.) In vitro differences in gene expression or function due to SNPs therefore have to be interpreted with caution when several other polymorphisms within the same gene may also alter functionality in vitro and in vivo. This notion may explain some of the controversial findings with regard to associations of individual SNPs in polymorphic genes (e.g. IL-4Rα).

The importance of haplotype analysis is further supported by the following studies. Seven SNPs in the IL-13 gene have been shown to be tightly linked [19], and therefore association studies of individual SNPs with the assumption of independent inheritance cannot easily be performed. Also, several SNPs within the IL-4Rα gene have been identified (see Supplementary Table 3). An association of two individual SNPs (S503P and Q576R) with decreased serum IgE levels was observed in a Caucasian population; however, most significant results with regard to low IgE levels were seen when both SNPs occurred together [20].

Similarly, Ober et al. performed TDT analysis for IL-4Rα SNPs and haplotypes in four populations. Again, the strongest evidence for linkage to asthma and/or atopy was observed with two-locus haplotype analysis [21].

Gene–gene interactions

Gene–gene interactions also have to be taken into consideration; for example, when both the genes encoding pro-inflammatory cytokines (i.e. IL-13) as well as their receptors (IL-4Rα) and/or genes involved in signal transduction (STAT6) bear polymorphisms associated with disease. The first studies have demonstrated the feasibility and importance of gene–gene interaction in atopy [22].

Gene–environment interactions

Pharmacogenetics

A marked disparity in treatment response to pharmacotherapy is observed in asthma (as well as in many other diseases). Variations in genes encoding proteins that interact with specific drugs or drug metabolism are likely to contribute to variability in treatment response. The best examined gene with regard to pharmacogenetics is the gene encoding the enzyme cytochrome p450, for which various alterations that affect the metabolism of multiple drugs have been described. Gene chips for the determination of p450 alleles are commercially available in Sweden and North America (reviewed in [23]).

Pharmacotherapy of asthma and atopy comprises β-agonists, corticosteroids, anti-histamines (H1-receptor antagonists) and leukotriene (receptor) antagonists. The following pharmacogenetic studies have been performed.

β₂-agonists

β₂-agonists are the most widely used drugs in the treatment of asthma. They exert their primary effect on the β₂AR of bronchial smooth muscle. The gene encoding the β₂AR maps to chromosome 5q33 and is the best examined candidate gene with regard to pharmacogenetic studies in asthma. Several SNPs within the coding region and the promoter of the β₂AR have been identified (summarized in [24]; see also Supplementary Table 3). Three mutations that result in amino acid changes of the mature protein (Gly16Arg, Gln27Glu, and Thr164Ile) lead to functional changes. The Gly16 variant was shown to undergo enhanced agonist-promoted downregulation in vitro. Interestingly, a strong association of the Gly16 polymorphism and nocturnal asthma could be demonstrated [25], which may explain the β₂AR downregulation observed in nocturnal asthmatics but not in non-nocturnal asthmatics [26].

Conflicting results have been reported with regard to β₂AR SNPs and response to β₂-agonists (summarized in Supplementary Table 3). A large multicenter study demonstrated that patients homozygous for the Arg16 variant developed a decline in peak flow when using albuterol on a regular basis [27]. However, a recent haplotype analysis [24] indicated that β₂AR SNPs are not independently transmitted and should presumably not be tested separately for associations with asthma or differences in drug response. Drysdale et al. demonstrated that only a limited number of β₂AR haplotypes can be found in several ethnic groups, far less than theoretically possible. Furthermore, response to β₂-agonists in asthmatic individuals significantly related to distinct haplotypes but not to individual SNPs. Consistent with the in vivo data, transfection of cells with the β₂AR haplotype associated with a better response to β₂-agonists resulted in significant greater mRNA levels and β₂AR receptor density compared with the lower response haplotype [24].

Corticosteroids

Despite the large variability in the steroid response of asthmatic individuals, genetic variations in the glucocorticoid receptor gene have as yet to be identified in steroid-dependent asthmatics.

Anti-histamines

No functionally relevant polymorphism has been found in the H1-histamine receptor gene [23]. However, a functional mutation in the gene encoding the histamine-degrading enzyme N-methyltransferase has been related to asthma [28].

Leukotriene antagonists

Leukotrienes (LTC₄, LTD₄, LTE₄) contribute to airway inflammation and bronchoconstriction in asthmatic individuals. 5-lipoxygenase (5-LO) (gene symbol, ALOX5; chromosome, 10q11.2) is a crucial enzyme in the synthesis of leukotrienes. The activity of 5-LO determines, at least in part, the concentration of leukotrienes in the airways. Drazen et al. [29] described frequently occurring mutations in the 5-LO promoter (three to six tandem repeats of an Sp-1 binding site, with the wild-type allele having five copies) that result in a decreased transcriptional activity. In patients with asthma, only those individuals that expressed the wild-type 5-LO promoter responded well to therapy with a 5-LO inhibitor (ABT-761, the drug was never marketed), whereas individuals with both 5-LO promoter alleles mutated showed no significant improvement of lung function when treated. It has not yet been examined whether these mutations also affect the responses of asthma patients to leukotriene receptor antagonists (e.g. montelukast, zafirlukast).

Sanak et al. described a polymorphism within the leukotriene C4 synthase promoter that resulted in higher risk of aspirin-induced asthma. This genetic variant may also alter response to treatment with drugs directed against leukotrienes [30].

In conclusion, the studies by Drazen et al. [29] and Drysdale et al. [24] in particular indicate that genetic testing may help to predict drug response and may eventually be used to optimize individual pharmacotherapy.

Genetics of host-defence

Apart from pharmacogenetic studies, the analysis of gene–environment interactions to date is hypothesis driven. The difficulties in quantifying and characterizing environmental risk factors for atopy (including onset and length of period of exposure) make these studies a challenge. Very high numbers of affected and unaffected subjects carefully characterized (longitudinally) for both the environmental setting and disease expression may be required to test for interactions between genetic variants and non-genetic influences.

However, recent genetic studies support the 'hygiene hypothesis', which postulates that atopy may be the result of a misdirected immune response in the absence of infection.

First, resistance to Schistosoma mansoni [31] and Plasmodium falciparum blood levels [32] (two independent studies) were linked to chromosome 5q31-33, a region (containing the IL-4 cytokine gene cluster) that has shown strong evidence for linkage to atopy-associated traits. Furthermore, a major locus closely linked to the interferon-γ receptor gene appears to control the switch from a T helper 2 to a T helper 1 cytokine profile during S. mansoni infection [33,34].

Second, SNPs within the FcεRI-β gene have been related to increased total serum IgE levels in heavily parasitized Australian aborigines, indicating a protective role in parasitic infection [35]. These SNPs have also been related to asthma, bronchial hyperresponsiveness, AD and atopy (see Supplementary Table 3). FcεRI-β maps to 11q13, a region that showed evidence for linkage to asthma and associated traits in multiple studies (Supplementary Table 3).

Finally, a polymorphism in the β₂AR encoding gene (Arg16) that has been related to asthma (see Supplementary Table 3) was also associated with higher levels of parasitic infection [36].

Ethnic differences in 'host defense' and 'atopy' genes

Evolutionary pressure with regard to infectious agents has differed significantly between continents. Significant ethnic differences in genes involved in immune defense mechanisms have been reported and may be based on differences in natural selection over the past centuries. Racial differences in genes involved in both host defense and allergic inflammation can best be demonstrated for CC chemokines and their receptors. CC chemokines have been shown to be crucial mediators of the allergic inflammation due to their potent chemoattractant properties for eosinophils, basophils and T cells [37]. Observations with regard to ethnic differences are as follows.

Evidence for linkage to chromosome 17q11.2 (a region that contains the CC chemokine gene cluster) has been reported in African Americans [38] but not in any Caucasian population (Supplementary Table 1).

A 32 base pair deletion in the CC chemokine receptor CCR5 renders individuals resistant to infection with macrophage-tropic HIV strains. This mutation is found in >10% of Caucasians, whereas it cannot be found in African populations [39]. A reduced risk of asthma was reported for carriers of the CCR5 deletion [40]. However, this could not be confirmed by Mitchell et al. [41].

In contrast to Caucasian individuals, the Duffy Antigen/Receptor for Chemokines is not expressed on red blood cells in the vast majority of African people (a point mutation in the Duffy promoter abolishes erythrocyte gene expression). This confers an evolutionary advantage since Duffy-negative erythrocytes are resistant to infection by Plasmodium vivax, which is endemic in most of Africa. Duffy has been shown to bind with high affinity to chemokines of both the CXC and CC classes, and is believed to function as a clearance receptor for chemokines (reviewed in [42]). It can therefore be hypothesized that higher or longer exposure to chemokines due to the absence of Duffy on erythrocytes might contribute to asthma pathogenesis in subjects of African descent.

A functional mutation in the proximal promoter of the CC chemokine RANTES was significantly more frequent among individuals of African descent compared with Caucasian subjects [43]. This mutation was associated with AD [43], asthma and atopy [44].

The 3' untranslated region of eotaxin has shown a much higher degree of polymorphism in African American and Afro-Caribbean individuals than in Caucasians. Polymorphic alleles were in linkage disequilibrium with asthma in both African American and Afro-Caribbean families, but not in Caucasian families [45]

Ethnic differences have also been described for various other genes involved in the allergic inflammation (e.g. IL-4Rα [21], β₂AR [24]). We can therefore speculate that inconsistent findings in the genetic studies of asthma and atopy summarized in this article may partly be explained by ethnic differences in nature and frequencies of genetic variants in disease susceptibility genes. We can also speculate that ethnic differences in inflammatory genes (in addition to environmental factors) may also underlie the significant worldwide differences in the prevalence of asthma, allergic rhinitis, and AD [46].

Conclusion

Asthma and atopy are complex, multifactorial disorders. Major strides have been made in identifying chromosomal regions and candidate genes linked to asthma. However, the significant increase in the prevalence of atopy-related disorders over the past decades cannot be explained by changes in gene frequencies. It is rather probable that various pre-existing genetic factors interacting with a dramatically changing environment (decline of infectious diseases, change in diet, immunizations, and others) have rendered a large percentage of the population susceptible to asthma and atopy. Genetic variations that evolved to improve resistance to infections may very probably be misdirected to promote allergic inflammation in the absence of infection in Western societies. Redundancies in host defense mechanisms may explain the large number of chromosomal regions as well as a steadily growing number of genetic variants related to atopy. Inconsistent findings summarized in this article may be explained by ethnic differences in host defense genes, but also by limitations to taking gene–gene as well as gene–environment interactions into account. Large prospective, multicenter studies, in addition to retrospective collaborations as described previously [14], may help to better understand genetic and environmental risk factors for atopy.

Acknowledgement

This article was supported by BMBF grant 01GC0002.

von Mutius E, Martinez FD, Fritzsch C, Nicolai T, Roell G, Thiemann HH: Prevalence of asthma and atopy in two areas of West and East Germany. Am J Respir Crit Care Med. 1994, 149: 358-364.PubMed

von Mutius E, Braun-Fahrlander C, Schierl R, Riedler J, Ehlermann S, Maisch S, Waser M, Nowak D: Exposure to endotoxin or other bacterial components might protect against the development of atopy. Clin Exp Allergy. 2000, 30: 1230-1234. 10.1046/j.1365-2222.2000.00959.x.PubMed

von Mutius E, Martinez FD, Fritzsch C, Nicolai T, Reitmeir P, Thiemann HH: Skin test reactivity and number of siblings. BMJ. 1994, 308: 692-695.PubMedPubMedCentral

Von Ehrenstein OS, Von Mutius E, Illi S, Baumann L, Bohm O, von Kries R: Reduced risk of hay fever and asthma among children of farmers. Clin Exp Allergy. 2000, 30: 187-193. 10.1046/j.1365-2222.2000.00801.x.PubMed

Illi S, von Mutius E, Lau S, Bergmann R, Niggemann B, Sommer-feld C, Wahn U: Early childhood infectious diseases and the development of asthma up to school age: a birth cohort study. BMJ. 2001, 322: 390-395. 10.1136/bmj.322.7283.390.PubMedPubMedCentral

Gereda JE, Leung DY, Thatayatikom A, Streib JE, Price MR, Klinnert MD, Liu AH: Relation between house-dust endotoxin exposure, type 1 T-cell development, and allergen sensitisa-tion in infants at high risk of asthma. Lancet. 2000, 355: 1680-1683. 10.1016/S0140-6736(00)02239-X.PubMed

Sandford A, Weir T, Pare P: The genetics of asthma. Am J Respir Crit Care Med. 1996, 153: 1749-1765.PubMed

Skadhauge LR, Christensen K, Kyvik KO, Sigsgaard T: Genetic and environmental influence on asthma: a population-based study of 11,688 Danish twin pairs. Eur Respir J. 1999, 13: 8-14. 10.1183/09031936.99.13100899.PubMed

Lander ES, Schork NJ: Genetic dissection of complex traits. Science. 1994, 265: 2037-2048.PubMed

10.

Barnes KC: Atopy and asthma genes – where do we stand?. Allergy. 2000, 55: 803-817. 10.1034/j.1398-9995.2000.00123.x.PubMed

11.

Cookson W: The alliance of genes and environment in asthma and allergy. Nature. 1999, 402: B5-B11. 10.1038/35037002.PubMed

12.

Ober C, Moffatt MF: Contributing factors to the pathobiology. The genetics of asthma. Clin Chest Med. 2000, 21: 245-261.PubMed

13.

Palmer LJ, Cookson WO: Genomic approaches to understanding asthma. Genome Res. 2000, 10: 1280-1287. 10.1101/gr.143400.PubMed

14.

Lonjou C, Barnes K, Chen H, Cookson WO, Deichmann KA, Hall IP, Holloway JW, Laitinen T, Palmer LJ, Wjst M, Morton NE: A first trial of retrospective collaboration for positional cloning in complex inheritance: assay of the cytokine region on chromosome 5 by the consortium on asthma genetics (COAG). Proc Natl Acad Sci USA. 2000, 97: 10942-10947. 10.1073/pnas.97.20.10942.PubMedPubMedCentral

15.

Palmer LJ, Lonjou C, Barnes K, Chen H, Cookson WO, Deichmann KA, Holloway JW, Laitinen T, Wjst M, Morton NE: Special Report: A retrospective collaboration on chromosome 5 by the International Consortium on Asthma Genetics (COAG). Clin Exp Allergy. 2001, 31: 152-154. 10.1046/j.1365-2222.2001.01040.x.PubMed

16.

Becker KG, Simon RM, Bailey-Wilson JE, Freidlin B, Biddison WE, McFarland HF, Trent JM: Clustering of non-major histocompatibility complex susceptibility candidate loci in human autoimmune diseases. Proc Natl Acad Sci USA. 1998, 95: 9979-9984. 10.1073/pnas.95.17.9979.PubMedPubMedCentral

17.

Cookson WO, Ubhi B, Lawrence R, Abecasis GR, Walley AJ, Cox HE, Coleman R, Leaves NI, Trembath RC, Moffatt MF, Harper JI: Genetic linkage of childhood atopic dermatitis to psoriasis susceptibility loci. Nat Genet. 2001, 27: 372-373. 10.1038/86867.PubMed

18.

Lee YA, Wahn U, Kehrt R, Tarani L, Businco L, Gustafsson D, Andersson F, Oranje AP, Wolkertstorfer A, Berg A, Hoffmann U, Kuster W, Wienker T, Ruschendorf F, Reis A: A major susceptibility locus for atopic dermatitis maps to chromosome 3q21. Nat Genet. 2000, 26: 470-473. 10.1038/82625.PubMed

19.

Graves PE, Kabesch M, Halonen M, Holberg CJ, Baldini M, Fritzsch C, Weiland SK, Erickson RP, von Mutius E, Martinez FD: A cluster of seven tightly linked polymorphisms in the IL-13 gene is associated with total serum IgE levels in three populations of white children. J Allergy Clin Immunol. 2000, 105: 506-513. 10.1067/mai.2000.104940.PubMed

20.

Kruse S, Japha T, Tedner M, Sparholt SH, Forster J, Kuehr J, Deichmann KA: The polymorphisms S503P and Q576R in the interleukin-4 receptor alpha gene are associated with atopy and influence the signal transduction. Immunology. 1999, 96: 365-371. 10.1046/j.1365-2567.1999.00705.x.PubMedPubMedCentral

21.

Ober C, Leavitt SA, Tsalenko A, Howard TD, Hoki DM, Daniel R, Newman DL, Wu X, Parry R, Lester LA, Solway J, Blumenthal M, King RA, Xu J, Meyers DA, Bleecker ER, Cox NJ: Variation in the interleukin 4-receptor alpha gene confers susceptibility to asthma and atopy in ethnically diverse populations. Am J Hum Genet. 2000, 66: 517-526. 10.1086/302781.PubMedPubMedCentral

22.

Barnes KC, Mathias RA, Nickel R, Freidhoff LR, Stockton ML, Xue X, Naidu RP, Levett PN, Casolaro V, Beaty TH: Testing for gene–gene interaction controlling total IgE in families from Barbados: Evidence of sensitivity regarding linkage heterogeneity among families. Genomics. 2001, 71: 246-251. 10.1006/geno.2000.6430.PubMed

23.

Hall IP: Pharmacogenetics of asthma. Eur Respir J. 2000, 15: 449-451. 10.1183/09031936.00.15344900.PubMed

24.

Drysdale CM, McGraw DW, Stack CB, Stephens JC, Judson RS, Nandabalan K, Arnold K, Ruano G, Liggett SB: Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc Natl Acad Sci USA. 2000, 97: 10483-10488. 10.1073/pnas.97.19.10483.PubMedPubMedCentral

25.

Turki J, Pak J, Green SA, Martin RJ, Liggett SB: Genetic polymorphisms of the beta 2-adrenergic receptor in nocturnal and nonnocturnal asthma. Evidence that Gly16 correlates with the nocturnal phenotype. J Clin Invest. 1995, 95: 1635-1641.PubMedPubMedCentral

26.

Szefler SJ, Ando R, Cicutto LC, Surs W, Hill MR, Martin RJ: Plasma histamine, epinephrine, cortisol, and leukocyte beta-adrenergic receptors in nocturnal asthma. Clin Pharmacol Ther. 1991, 49: 59-68.PubMed

27.

Israel E, Drazen JM, Liggett SB, Boushey HA, Cherniack RM, Chinchilli VM, Cooper DM, Fahy JV, Fish JE, Ford JG, Kraft M, Kunselman S, Lazarus SC, Lemanske RF, Martin RJ, McLean DE, Peters SP, Silverman EK, Sorkness CA, Szefler SJ, Weiss ST, Yandava CN: The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma. Am J Respir Crit Care Med. 2000, 162: 75-80.PubMed

28.

Yan L, Galinsky RE, Bernstein JA, Liggett SB, Weinshilboum RM: Histamine N-methyltransferase pharmacogenetics: association of a common functional polymorphism with asthma. Pharmacogenetics. 2000, 10: 261-266. 10.1097/00008571-200004000-00007.PubMed

29.

Drazen JM, Yandava CN, Dube L, Szczerback N, Hippensteel R, Pillari A, Israel E, Schork N, Silverman ES, Katz DA, Drajesk J: Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nat Genet. 1999, 22: 168-170. 10.1038/9680.PubMed

30.

Sanak M, Pierzchalska M, Bazan-Socha S, Szczeklik A: Enhanced expression of the leukotriene C(4) synthase due to overactive transcription of an allelic variant associated with aspirin-intolerant asthma. Am J Respir Cell Mol Biol. 2000, 23: 290-296.PubMed

31.

Marquet S, Abel L, Hillaire D, Dessein H, Kalil J, Feingold J, Weissenbach J, Dessein AJ: Genetic localization of a locus controlling the intensity of infection by Schistosoma mansoni on chromosome 5q31-q33. Nat Genet. 1996, 14: 181-184.PubMed

32.

Rihet P, Traore Y, Abel L, Aucan C, Traore-Leroux T, Fumoux F: Malaria in humans: Plasmodium falciparum blood infection levels are linked to chromosome 5q31-q33. Am J Hum Genet. 1998, 63: 498-505. 10.1086/301967.PubMedPubMedCentral

33.

Dessein AJ, Hillaire D, Elwali NE, Marquet S, Mohamed-Ali Q, Mirghani A, Henri S, Abdelhameed AA, Saeed OK, Magzoub MM, Abel L: Severe hepatic fibrosis in Schistosoma mansoni infection is controlled by a major locus that is closely linked to the interferon-gamma receptor gene. Am J Hum Genet. 1999, 65: 709-721. 10.1086/302526.PubMedPubMedCentral

34.

Roberts M, Butterworth AE, Kimani G, Kamau T, Fulford AJ, Dunne DW, Ouma JH, Sturrock RF: Immunity after treatment of human schistosomiasis: association between cellular responses and resistance to reinfection. Infect Immun. 1993, 61: 4984-4993.PubMedPubMedCentral

35.

Palmer LJ, Pare PD, Faux JA, Moffatt MF, Daniels SE, LeSouef PN, Bremner PR, Mockford E, Gracey M, Spargo R, Musk AW, Cookson WO: Fc epsilon R1-beta polymorphism and total serum IgE levels in endemically parasitized Australian aborigines. Am J Hum Genet. 1997, 61: 182-188.PubMedPubMedCentral

36.

Ramsay CE, Hayden CM, Tiller KJ, Burton PR, Hagel I, Palenque M, Lynch NR, Goldblatt J, LeSouef PN: Association of polymorphisms in the beta2-adrenoreceptor gene with higher levels of parasitic infection. Hum Genet. 1999, 104: 269-274. 10.1007/s004390050947.PubMed

37.

Nickel R, Beck LA, Stellato C, Schleimer RP: Chemokines and allergic disease. J Allergy Clin Immunol. 1999, 104: 723-742.PubMed

38.

A genome-wide search for asthma susceptibility loci in ethnically diverse populations. The Collaborative Study on the Genetics of Asthma (CSGA). Nat Genet. 1997, 15: 389-392.

39.

Martinson JJ, Chapman NH, Rees DC, Liu YT, Clegg JB: Global distribution of the CCR5 gene 32-basepair deletion. Nat Genet. 1997, 16: 100-103.PubMed

40.

Hall IP, Wheatley A, Christie G, McDougall C, Hubbard R, Helms PJ: Association of CCR5 delta32 with reduced risk of asthma. Lancet. 1999, 354: 1264-1265. 10.1016/S0140-6736(99)03425-X.PubMed

41.

Mitchell TJ, Walley AJ, Pease JE, Venables PJ, Wiltshire S, Williams TJ, Cookson WO: Delta 32 deletion of CCR5 gene and association with asthma or atopy. Lancet. 2000, 356: 1491-1492. 10.1016/S0140-6736(00)03144-5.PubMed

42.

Hadley TJ, Peiper SC: From malaria to chemokine receptor: the emerging physiologic role of the Duffy blood group antigen. Blood. 1997, 89: 3077-3091.PubMed

43.

Nickel RG, Casolaro V, Wahn U, Beyer K, Barnes KC, Plunkett BS, Freidhoff LR, Sengler C, Plitt JR, Schleimer RP, Caraballo L, Naidu RP, Levett PN, Beaty TH, Huang SK: Atopic dermatitis is associated with a functional mutation in the promoter of the C-C chemokine RANTES. J Immunol. 2000, 164: 1612-1616.PubMed

44.

Fryer AA, Spiteri MA, Bianco A, Hepple M, Jones PW, Strange RC, Makki R, Tavernier G, Smilie FI, Custovic A, Woodcock AA, Ollier WE, Hajeer AH: The -403 G → A promoter polymorphism in the RANTES gene is associated with atopy and asthma. Genes Immun. 2000, 1: 509-514. 10.1038/sj/gene/6363717.PubMed

45.

Nickel R, Barnes KC, Sengler C, Casolaro V, Freidhoff LR, Weber P, Naidu R, Caraballo L, Ehrlich E, Plitt J, Schleimer RP, Huang SK, Beaty T: Evidence for linkage of chemokine polymorphisms to asthma in populations of African descent [abstract]. J Allergy Clin Immunol. 1999, 103: S174-

46.

Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Lancet. 1998, 351: 1225-1232. 10.1016/S0140-6736(97)07302-9.

S1.

Hizawa N, Freidhoff LR, Chiu YF, Ehrlich E, Luehr CA, Anderson JL, Duffy DL, Dunston GM, Weber JL, Huang SK, Barnes KC, Marsh DG, Beaty TH: Genetic regulation of Dermatophagoides pteronyssinus-specific IgE responsiveness: a genome-wide multipoint linkage analysis in families recruited through 2 asthmatic sibs. Collaborative Study on the Genetics of Asthma (CSGA). J Allergy Clin Immunol. 1998, 102: 436-442.PubMed

S2.

Daniels SE, Bhattacharrya S, James A, Leaves NI, Young A, Hill MR, Faux JA, Ryan GF, le Souef PN, Lathrop GM, Musk AW, Cookson WO: A genome-wide search for quantitative trait loci underlying asthma. Nature. 1996, 383: 247-250. 10.1038/383247a0.PubMed

S3.

Ober C, Cox NJ, Abney M, Di Rienzo A, Lander ES, Changyaleket B, Gidley H, Kurtz B, Lee J, Nance M, Pettersson A, Prescott J, Richardson A, Schlenker E, Summerhill E, Willadsen S, Parry R: Genome-wide search for asthma susceptibility loci in a founder population. The Collaborative Study on the Genetics of Asthma. Hum Mol Genet. 1998, 7: 1393-1398. 10.1093/hmg/7.9.1393.PubMed

S4.

Ober C, Tsalenko A, Parry R, Cox NJ: A second-generation genome-wide screen for asthma-susceptibility alleles in a founder population. Am J Hum Genet. 2000, 67: 1154-1162.PubMedPubMedCentral

S5.

Wjst M, Fischer G, Immervoll T, Jung M, Saar K, Rueschendorf F, Reis A, Ulbrecht M, Gomolka M, Weiss EH, Jaeger L, Nickel R, Richter K, Kjellman NI, Griese M, von Berg A, Gappa M, Riedel F, Boehle M, van Koningsbruggen S, Schoberth P, Szczepanski R, Dorsch W, Silbermann M, Wichmann HE: A genome-wide search for linkage to asthma. German Asthma Genetics Group. Genomics. 1999, 58: 1-8. 10.1006/geno.1999.5806.PubMed

S6.

Yokouchi Y, Nukaga Y, Shibasaki M, Noguchi E, Kimura K, Ito S, Nishihara M, Yamakawa-Kobayashi K, Takeda K, Imoto N, Ichikawa K, Matsui A, Hamaguchi H, Arinami T: Significant evidence for linkage of mite-sensitive childhood asthma to chromosome 5q31-q33 near the interleukin 12 B locus by a genome-wide search in Japanese families. Genomics. 2000, 66: 152-160. 10.1006/geno.2000.6201.PubMed

S7.

Dizier MH, Besse-Schmittler C, Guilloud-Bataille M, Annesi-Maesano I, Boussaha M, Bousquet J, Charpin D, Degioanni A, Gormand F, Grimfeld A, Hochez J, Hyne G, Lockhart A, Luillier-Lacombe M, Matran R, Meunier F, Neukirch F, Pacheco Y, Parent V, Paty E, Pin I, Pison C, Scheinmann P, Thobie N, Vervloet D, Kauffmann F: Genome screen for asthma and related phenotypes in the french EGEA study. Am J Respir Crit Care Med. 2000, 162: 1812-1818.PubMed

S8.

Meyers DA, Postma DS, Panhuysen CI, Xu J, Amelung PJ, Levitt RC, Bleecker ER: Evidence for a locus regulating total serum IgE levels mapping to chromosome 5. Genomics. 1994, 23: 464-470. 10.1006/geno.1994.1524.PubMed

S9.

Marsh DG, Neely JD, Breazeale DR, Ghosh B, Freidhoff LR, Ehrlich-Kautzky E, Schou C, Krishnaswamy G, Beaty TH: Linkage analysis of IL4 and other chromosome 5q31.1 markers and total serum immunoglobulin E concentrations. Science. 1994, 264: 1152-1156.PubMed

S10.

Doull IJ, Lawrence S, Watson M, Begishvili T, Beasley RW, Lampe F, Holgate T, Morton NE: Allelic association of gene markers on chromosomes 5q and 11q with atopy and bronchial hyper-responsiveness. Am J Respir Crit Care Med. 1996, 153: 1280-1284.PubMed

S11.

Palmer LJ, Daniels SE, Rye PJ, Gibson NA, Tay GK, Cookson WO, Goldblatt J, Burton PR, LeSouef PN: Linkage of chromosome 5q and 11q gene markers to asthma-associated quantitative traits in Australian children. Am J Respir Crit Care Med. 1998, 158: 1825-1830.PubMed

S12.

Hizawa N, Freidhoff LR, Ehrlich E, Chiu YF, Duffy DL, Schou C, Dunston GM, Beaty TH, Marsh DG, Barnes KC, Huang SK: Genetic influences of chromosomes 5q31-q33 and 11q13 on specific IgE responsiveness to common inhaled allergens among African American families. Collaborative Study on the Genetics of Asthma (CSGA). J Allergy Clin Immunol. 1998, 102: 449-453.PubMed

S13.

Forrest S, Dunn K, Elliott K, Fitzpatrick E, Fullerton J, McCarthy M, Brown J, Hill D, Williamson R: Identifying genes predisposing to atopic eczema. J Allergy Clin Immunol. 1999, 104: 1066-1070.PubMed

S14.

Beyer K, Nickel R, Freidhoff L, Bjorksten B, Huang SK, Barnes KC, MacDonald S, Forster J, Zepp F, Wahn V, Beaty TH, Marsh DG, Wahn U: Association and linkage of atopic dermatitis with chromosome 13q12-14 and 5q31-33 markers. J Invest Dermatol. 2000, 115: 906-908. 10.1046/j.1523-1747.2000.00096.x.PubMed

S15.

Noguchi E, Shibasaki M, Arinami T, Takeda K, Maki T, Miyamoto T, Kawashima T, Kobayashi K, Hamaguchi H: Evidence for linkage between asthma/atopy in childhood and chromosome 5q31-q33 in a Japanese population. Am J Respir Crit Care Med. 1997, 156: 1390-1393.PubMed

S16.

Martinez FD, Solomon S, Holberg CJ, Graves PE, Baldini M, Erickson RP: Linkage of circulating eosinophils to markers on chromosome 5q. Am J Respir Crit Care Med. 1998, 158: 1739-1744.PubMed

S17.

Rioux JD, Stone VA, Daly MJ, Cargill M, Green T, Nguyen H, Nutman T, Zimmerman PA, Tucker MA, Hudson T, Goldstein AM, Lander E, Lin AY: Familial eosinophilia maps to the cytokine gene cluster on human chromosomal region 5q31-q33. Am J Hum Genet. 1998, 63: 1086-1094. 10.1086/302053.PubMedPubMedCentral

S18.

Postma DS, Bleecker ER, Amelung PJ, Holroyd KJ, Xu J, Panhuysen CI, Meyers DA, Levitt RC: Genetic susceptibility to asthma – bronchial hyperresponsiveness coinherited with a major gene for atopy. N Engl J Med. 1995, 333: 894-900. 10.1056/NEJM199510053331402.PubMed

S19.

Hizawa N, Collins G, Rafnar T, Huang SK, Duffy DL, Weber JL, Freidhoff LR, Ehrlich E, Marsh DG, Beaty TH, Barnes KC: Linkage analysis of Dermatophagoides pteronyssinus-specific IgE responsiveness with polymorphic markers on chromosome 6p21 (HLA-D region) in Caucasian families by the transmission/disequilibrium test. Collaborative Study on the Genetics of Asthma (CSGA). J Allergy Clin Immunol. 1998, 102: 443-448.PubMed

S20.

Caraballo LR, Hernandez M: HLA haplotype segregation in families with allergic asthma. Tissue Antigens. 1990, 35: 182-186.PubMed

S21.

Cookson WO, Sharp PA, Faux JA, Hopkin JM: Linkage between immunoglobulin E responses underlying asthma and rhinitis and chromosome 11q. Lancet. 1989, 1: 1292-1295. 10.1016/S0140-6736(89)92687-1.PubMed

S22.

Young RP, Sharp PA, Lynch JR, Faux JA, Lathrop GM, Cookson WO, Hopkin JM: Confirmation of genetic linkage between atopic IgE responses and chromosome 11q13. J Med Genet. 1992, 29: 236-238.PubMedPubMedCentral

S23.

van Herwerden L, Harrap SB, Wong ZY, Abramson MJ, Kutin JJ, Forbes AB, Raven J, Lanigan A, Walters EH: Linkage of high-affinity IgE receptor gene with bronchial hyperreactivity, even in absence of atopy. Lancet. 1995, 346: 1262-1265. 10.1016/S0140-6736(95)91863-9.PubMed

S24.

Shirakawa T, Hashimoto T, Furuyama J, Takeshita T, Morimoto K: Linkage between severe atopy and chromosome 11q13 in Japanese families. Clin Genet. 1994, 46: 228-232.PubMed

S25.

Collee JM, ten Kate LP, de Vries HG, Kliphuis JW, Bouman K, Scheffer H, Gerritsen J: Allele sharing on chromosome 11q13 in sibs with asthma and atopy [letter]. Lancet. 1993, 342: 936-10.1016/0140-6736(93)91988-X.PubMed

S26.

Folster-Holst R, Moises HW, Yang L, Fritsch W, Weissenbach J, Christophers E: Linkage between atopy and the IgE high-affinity receptor gene at 11q13 in atopic dermatitis families. Hum Genet. 1998, 102: 236-239. 10.1007/s004390050685.PubMed

S27.

Wjst M, Wichmann HE: Collaborative study on the genetics of asthma in Germany. Clin Exp Allergy. 1995, 25(suppl 2): 23-25.

S28.

Wilkinson J, Grimley S, Collins A, Thomas NS, Holgate ST, Morton N: Linkage of asthma to markers on chromosome 12 in a sample of 240 families using quantitative phenotype scores. Genomics. 1998, 53: 251-259. 10.1006/geno.1998.5485.PubMed

S29.

Barnes KC, Freidhoff LR, Nickel R, Chiu YF, Juo SH, Hizawa N, Naidu RP, Ehrlich E, Duffy DL, Schou C, Levett PN, Marsh DG, Beaty TH: Dense mapping of chromosome 12q13.12-q23.3 and linkage to asthma and atopy. J Allergy Clin Immunol. 1999, 104: 485-491.PubMed

S30.

Barnes KC, Neely JD, Duffy DL, Freidhoff LR, Breazeale DR, Schou C, Naidu RP, Levett PN, Renault B, Kucherlapati R, Iozzino S, Ehrlich E, Beaty TH, Marsh DG: Linkage of asthma and total serum IgE concentration to markers on chromosome 12q: evidence from Afro-Caribbean and Caucasian populations. Genomics. 1996, 37: 41-50. 10.1006/geno.1996.0518.PubMed

S31.

Nickel R, Wahn U, Hizawa N, Maestri N, Duffy DL, Barnes KC, Beyer K, Forster J, Bergmann R, Zepp F, Wahn V, Marsh DG: Evidence for linkage of chromosome 12q15-q24.1 markers to high total serum IgE concentrations in children of the German Multicenter Allergy Study. Genomics. 1997, 46: 159-162. 10.1006/geno.1997.5013.PubMed

S32.

Kimura K, Noguchi E, Shibasaki M, Arinami T, Yokouchi Y, Takeda K, Yamakawa-Kobayashi K, Matsui A, Hamaguchi H: Linkage and association of atopic asthma to markers on chromosome 13 in the Japanese population. Hum Mol Genet. 1999, 8: 1487-1490. 10.1093/hmg/8.8.1487.PubMed

S33.

Heinzmann A, Plesnar C, Kuehr J, Forster J, Deichmann KA: Common polymorphisms in the CTLA-4 and CD28 genes at 2q33 are not associated with asthma or atopy. Eur J Immunogenet. 2000, 27: 57-61. 10.1046/j.1365-2370.2000.00198.x.PubMed

S34.

Noguchi E, Shibasaki M, Arinami T, Takeda K, Yokouchi Y, Kawashima T, Yanagi H, Matsui A, Hamaguchi H: Association of asthma and the interleukin-4 promoter gene in Japanese. Clin Exp Allergy. 1998, 28: 449-453. 10.1046/j.1365-2222.1998.00256.x.PubMed

S35.

Rosenwasser LJ, Klemm DJ, Dresback JK, Inamura H, Mascali JJ, Klinnert M, Borish L: Promoter polymorphisms in the chromosome 5 gene cluster in asthma and atopy. Clin Exp Allergy. 1995, 25(suppl 2): 74-78.

S36.

Walley AJ, Cookson WO: Investigation of an interleukin-4 promoter polymorphism for associations with asthma and atopy. J Med Genet. 1996, 33: 689-692.PubMedPubMedCentral

S37.

Burchard EG, Silverman EK, Rosenwasser LJ, Borish L, Yandava C, Pillari A, Weiss ST, Hasday J, Lilly CM, Ford JG, Drazen JM: Association between a sequence variant in the IL-4 gene promoter and FEV(1) in asthma. Am J Respir Crit Care Med. 1999, 160: 919-922.PubMed

S38.

Kawashima T, Noguchi E, Arinami T, Yamakawa-Kobayashi K, Nakagawa H, Otsuka F, Hamaguchi H: Linkage and association of an interleukin 4 gene polymorphism with atopic dermatitis in Japanese families. J Med Genet. 1998, 35: 502-504.PubMedPubMedCentral

S39.

Dizier MH, Sandford A, Walley A, Philippi A, Cookson W, Deme-nais F: Indication of linkage of serum IgE levels to the inter-leukin-4 gene and exclusion of the contribution of the (-590 C to T) interleukin-4 promoter polymorphism to IgE variation. Genet Epidemiol. 1999, 16: 84-94. 10.1002/(SICI)1098-2272(1999)16:1<84::AID-GEPI7>3.3.CO;2-4.PubMed

S40.

Suzuki I, Yamaguchi E, Hizawa N, Itoh A, Kawakami Y: A new polymorphism in the 5' flanking region of the human inter-leukin (IL)-4 gene. Immunogenetics. 1999, 49: 738-739. 10.1007/s002510050677.PubMed

S41.

Pereira E, Goldblatt J, Rye P, Sanderson C, Le Souef P: Mutation analysis of interleukin-5 in an asthmatic cohort. Hum Mutat. 1998, 11: 51-54. 10.1002/(SICI)1098-1004(1998)11:1<51::AID-HUMU8>3.3.CO;2-F.PubMed

S42.

van der Pouw Kraan TC, van Veen A, Boeije LC, van Tuyl SA, de Groot ER, Stapel SO, Bakker A, Verweij CL, Aarden LA, van der Zee JS: An IL-13 promoter polymorphism associated with increased risk of allergic asthma. Genes Immun. 1999, 1: 61-65. 10.1038/sj.gene.6363630.PubMed

S43.

Liu X, Nickel R, Beyer K, Wahn U, Ehrlich E, Freidhoff LR, Bjork-sten B, Beaty TH, Huang SK: An IL13 coding region variant is associated with a high total serum IgE level and atopic dermatitis in the German multicenter atopy study (MAS-90). J Allergy Clin Immunol. 2000, 106: 167-170. 10.1067/mai.2000.107935.PubMed

S44.

Heinzmann A, Mao XQ, Akaiwa M, Kreomer RT, Gao PS, Ohshima K, Umeshita R, Abe Y, Braun S, Yamashita T, Roberts MH, Sugi-moto R, Arima K, Arinobu Y, Yu B, Kruse S, Enomoto T, Dake Y, Kawai M, Shimazu S, Sasaki S, Adra CN, Kitaichi M, Inoue H, Yamauchi K, Tomichi N, Kurimoto F, Hamasaki N, Hopkin JM, Izuhara K, Shirakawa T, Deichmann KA: Genetic variants of IL-13 signalling and human asthma and atopy. Hum Mol Genet. 2000, 9: 549-559. 10.1093/hmg/9.4.549.PubMed

S45.

Summerhill E, Leavitt SA, Gidley H, Parry R, Solway J, Ober C: Beta(2)-adrenergic receptor Arg16/Arg16 genotype is associated with reduced lung function, but not with asthma, in the Hutterites. Am J Respir Crit Care Med. 2000, 162: 599-602.PubMed

S46.

Holloway JW, Dunbar PR, Riley GA, Sawyer GM, Fitzharris PF, Pearce N, Le Gros GS, Beasley R: Association of beta2-adren-ergic receptor polymorphisms with severe asthma. Clin Exp Allergy. 2000, 30: 1097-1103. 10.1046/j.1365-2222.2000.00929.x.PubMed

S47.

Reihsaus E, Innis M, MacIntyre N, Liggett SB: Mutations in the gene encoding for the beta 2-adrenergic receptor in normal and asthmatic subjects. Am J Respir Cell Mol Biol. 1993, 8: 334-339.PubMed

S48.

Deichmann KA, Schmidt A, Heinzmann A, Kruse S, Forster J, Kuehr J: Association studies on beta2-adrenoceptor polymorphisms and enhanced IgE responsiveness in an atopic population. Clin Exp Allergy. 1999, 29: 794-799. 10.1046/j.1365-2222.1999.00571.x.PubMed

S49.

Tan S, Hall IP, Dewar J, Dow E, Lipworth B: Association between beta 2-adrenoceptor polymorphism and susceptibility to bronchodilator desensitisation in moderately severe stable asthmatics. Lancet. 1997, 350: 995-999. 10.1016/S0140-6736(97)03211-X.PubMed

S50.

Dewar JC, Wilkinson J, Wheatley A, Thomas NS, Doull I, Morton N, Lio P, Harvey JF, Liggett SB, Holgate ST, Hall IP: The gluta-mine 27 beta2-adrenoceptor polymorphism is associated with elevated IgE levels in asthmatic families. J Allergy Clin Immunol. 1997, 100: 261-265.PubMed

S51.

Hall IP, Wheatley A, Wilding P, Liggett SB: Association of Glu 27 beta 2-adrenoceptor polymorphism with lower airway reactivity in asthmatic subjects. Lancet. 1995, 345: 1213-1214. 10.1016/S0140-6736(95)91994-5.PubMed

S52.

Noguchi E, Shibasaki M, Arinami T, Yamakawa-Kobayashi K, Yok-ouchi Y, Takeda K, Matsui A, Hamaguchi H: Mutation screening of interferon regulatory factor 1 gene (IRF-1) as a candidate gene for atopy/asthma. Clin Exp Allergy. 2000, 30: 1563-1567. 10.1046/j.1365-2222.2000.00916.x.

S53.

Baldini M, Lohman IC, Halonen M, Erickson RP, Holt PG, Martinez FD: A Polymorphism* in the 5' flanking region of the CD14 gene is associated with circulating soluble CD14 levels and with total serum immunoglobulin E. Am J Respir Cell Mol Biol. 1999, 20: 976-983.PubMed

S54.

Gao PS, Mao XQ, Baldini M, Roberts MH, Adra CN, Shirakawa T, Holt PG, Martinez FD, Hopkin JM: Serum total IgE levels and CD14 on chromosome 5q31. Clin Genet. 1999, 56: 164-165. 10.1034/j.1399-0004.1999.560213.x.PubMed

S55.

Van Sambeek R, Stevenson DD, Baldasaro M, Lam BK, Zhao J, Yoshida S, Yandora C, Drazen JM, Penrose JF: 5' flanking region polymorphism of the gene encoding leukotriene C4 synthase does not correlate with the aspirin-intolerant asthma phenotype in the United States. J Allergy Clin Immunol. 2000, 106: 72-76. 10.1067/mai.2000.107603.PubMed

S56.

Moffatt MF, Cookson WO: The genetics of specific allergy. Monogr Allergy. 1996, 33: 71-96.PubMed

S57.

Li Kam, Wa TC, Mansur AH, Britton J, Williams G, Pavord I, Richards K, Campbell DA, Morton N, Holgate ST, Morrison JF: Association between -308 tumour necrosis factor promoter polymorphism and bronchial hyperreactivity in asthma. Clin Exp Allergy. 1999, 29: 1204-1208. 10.1046/j.1365-2222.1999.00638.x.

S58.

Moffatt MF, Cookson WO: Tumour necrosis factor haplotypes and asthma. Hum Mol Genet. 1997, 6: 551-554. 10.1093/hmg/6.4.551.PubMed

S59.

Albuquerque RV, Hayden CM, Palmer LJ, Laing IA, Rye PJ, Gibson NA, Burton PR, Goldblatt J, Lesouef PN: Association of polymorphisms within the tumour necrosis factor (TNF) genes and childhood asthma. Clin Exp Allergy. 1998, 28: 578-584. 10.1046/j.1365-2222.1998.00273.x.PubMed

S60.

Kruse S, Mao XQ, Heinzmann A, Blattmann S, Roberts MH, Braun S, Gao PS, Forster J, Kuehr J, Hopkin JM, Shirakawa T, Deichmann KA: The Ile198Thr and Ala379Val variants of plasmatic PAF-acetylhydrolase impair catalytical activities and are associated with atopy and asthma. Am J Hum Genet. 2000, 66: 1522-1530. 10.1086/302901.PubMedPubMedCentral

S61.

Laing IA, Goldblatt J, Eber E, Hayden CM, Rye PJ, Gibson NA, Palmer LJ, Burton PR, Le Souef PN: A polymorphism of the CC16 gene is associated with an increased risk of asthma. J Med Genet. 1998, 35: 463-467.PubMedPubMedCentral

S62.

Gao PS, Mao XQ, Kawai M, Enomoto T, Sasaki S, Tanabe O, Yoshimura K, Shaldon SR, Dake Y, Kitano H, Coull P, Shirakawa T, Hopkin JM: Negative association between asthma and variants of CC16(CC10) on chromosome 11q13 in British and Japanese populations. Hum Genet. 1998, 103: 57-59. 10.1007/s004390050783.PubMed

S63.

Shirakawa T, Li A, Dubowitz M, Dekker JW, Shaw AE, Faux JA, Ra C, Cookson WO, Hopkin JM: Association between atopy and variants of the beta subunit of the high-affinity immunoglobulin E receptor. Nat Genet. 1994, 7: 125-129.PubMed

S64.

Shirakawa T, Mao XQ, Sasaki S, Enomoto T, Kawai M, Morimoto K, Hopkin J: Association between atopic asthma and a coding variant of Fc epsilon RI beta in a Japanese population [letter]. Hum Mol Genet. 1996, 5: 2068-10.1093/hmg/5.8.1129.PubMed

S65.

Hill MR, James AL, Faux JA, Ryan G, Hopkin JM, le Souef P, Musk AW, Cookson WO: Fc epsilon RI-beta polymorphism and risk of atopy in a general population sample. BMJ. 1995, 311: 776-779.PubMedPubMedCentral

S66.

Hill MR, Cookson WO: A new variant of the beta subunit of the high-affinity receptor for immunoglobulin E (Fc epsilon RI-beta E237G): associations with measures of atopy and bronchial hyper-responsiveness. Hum Mol Genet. 1996, 5: 959-962. 10.1093/hmg/5.7.959.PubMed

S67.

Ishizawa M, Shibasaki M, Yokouchi Y, Noguchi E, Arinami T, Yamakawa-Kobayashi K, Matsui A, Hamaguchi H: No association between atopic asthma and a coding variant of Fc epsilon R1 beta in a Japanese population. J Hum Genet. 1999, 44: 308-311. 10.1007/s100380050166.PubMed

S68.

Palmer LJ, Rye PJ, Gibson NA, Moffatt MF, Goldblatt J, Burton PR, Cookson WO, Lesouef PN: Association of FcepsilonR1-beta polymorphisms with asthma and associated traits in Australian asthmatic families. Clin Exp Allergy. 1999, 29: 1555-1562. 10.1046/j.1365-2222.1999.00718.x.PubMed

S69.

Cox HE, Moffatt MF, Faux JA, Walley AJ, Coleman R, Trembath RC, Cookson WO, Harper JI: Association of atopic dermatitis to the beta subunit of the high affinity immunoglobulin E receptor. Br J Dermatol. 1998, 138: 182-187. 10.1046/j.1365-2133.1998.02108.x.PubMed

S70.

Hizawa N, Yamaguchi E, Jinushi E, Kawakami Y: A common FCER1B gene promoter polymorphism influences total serum IgE levels in a Japanese population. Am J Respir Crit Care Med. 2000, 161: 906-909.PubMed

S71.

Fryer AA, Bianco A, Hepple M, Jones PW, Strange RC, Spiteri MA: Polymorphism at the glutathione S-transferase GSTP1 locus. A new marker for bronchial hyperresponsiveness and asthma. Am J Respir Crit Care Med. 2000, 161: 1437-1442.PubMed

S72.

Gao PS, Mao XQ, Roberts MH, Arinobu Y, Akaiwa M, Enomoto T, Dake Y, Kawai M, Sasaki S, Hamasaki N, Izuhara K, Shirakawa T, Hopkin JM: Variants of STAT6 (signal transducer and activator of transcription 6) in atopic asthma. J Med Genet. 2000, 37: 380-382. 10.1136/jmg.37.5.380a.PubMedPubMedCentral

S73.

Hayden C, Pereira E, Rye P, Palmer L, Gibson N, Palenque M, Hagel I, Lynch N, Goldblatt J, Lesouef P: Mutation screening of interferon-gamma (IFNgamma) as a candidate gene for asthma. Clin Exp Allergy. 1997, 27: 1412-1416. 10.1046/j.1365-2222.1997.1800979.x.PubMed

S74.

Wechsler ME, Grasemann H, Deykin A, Silverman EK, Yandava CN, Israel E, Wand M, Drazen JM: Exhaled nitric oxide in patients with asthma. Association with nos1 genotype. Am J Respir Crit Care Med. 2000, 162: 2043-2047.PubMed

S75.

Moffatt MF, Schou C, Faux JA, Cookson WO: Germline TCR-A restriction of immunoglobulin E responses to allergen. Immunogenetics. 1997, 46: 226-230. 10.1007/s002510050266.PubMed

S76.

Mao XQ, Shirakawa T, Yoshikawa T, Yoshikawa K, Kawai M, Sasaki S, Enomoto T, Hashimoto T, Furuyama J, Hopkin JM, Morimoto K: Association between genetic variants of mast-cell chymase and eczema. Lancet. 1996, 348: 581-583. 10.1016/S0140-6736(95)10244-2.PubMed

S77.

Mao XQ, Shirakawa T, Enomoto T, Shimazu S, Dake Y, Kitano H, Hagihara A, Hopkin JM: Association between variants of mast cell chymase gene and serum IgE levels in eczema. Hum Hered. 1998, 48: 38-41. 10.1159/000022782.PubMed

S78.

Kawashima T, Noguchi E, Arinami T, Kobayashi K, Otsuka F, Ham-aguchi H: No evidence for an association between a variant of the mast cell chymase gene and atopic dermatitis based on case-control and haplotype-relative-risk analyses. Hum Hered. 1998, 48: 271-274. 10.1159/000022815.PubMed

S79.

Pascale E, Tarani L, Meglio P, Businco L, Battiloro E, Cimino-Reale G, Verna R, D'Ambrosio E: Absence of association between a variant of the mast cell chymase gene and atopic dermatitis in an Italian population. Hum Hered. 2001, 51: 177-179. 10.1159/000053339.PubMed

S80.

Tanaka K, Sugiura H, Uehara M, Sato H, Hashimoto-Tamaoki T, Furuyama J: Association between mast cell chymase genotype and atopic eczema: comparison between patients with atopic eczema alone and those with atopic eczema and atopic respiratory disease. Clin Exp Allergy. 1999, 29: 800-803. 10.1046/j.1365-2222.1999.00388.x.PubMed

S81.

Hershey GK, Friedrich MF, Esswein LA, Thomas ML, Chatila TA: The association of atopy with a gain-of-function mutation in the alpha subunit of the interleukin-4 receptor. N Engl J Med. 1997, 337: 1720-1725. 10.1056/NEJM199712113372403.PubMed

S82.

Rosa-Rosa L, Zimmermann N, Bernstein JA, Rothenberg ME, Khurana Hershey GK: The R576 IL-4 receptor alpha allele correlates with asthma severity. J Allergy Clin Immunol. 1999, 104: 1008-1014.PubMed

S83.

Patuzzo C, Trabetti E, Malerba G, Martinati LC, Boner AL, Pescollderungg L, Zanoni G, Pignatti PF: No linkage or association of the IL-4Ralpha gene Q576R mutation with atopic asthma in Italian families. J Med Genet. 2000, 37: 382-384. 10.1136/jmg.37.5.382.PubMedPubMedCentral

S84.

Oiso N, Fukai K, Ishii M: Interleukin 4 receptor alpha chain polymorphism Gln551Arg is associated with adult atopic dermatitis in Japan. Br J Dermatol. 2000, 142: 1003-1006. 10.1046/j.1365-2133.2000.03485.x.PubMed

S85.

Mitsuyasu H, Izuhara K, Mao XQ, Gao PS, Arinobu Y, Enomoto T, Kawai M, Sasaki S, Dake Y, Hamasaki N, Shirakawa T, Hopkin JM: Ile50Val variant of IL4R alpha upregulates IgE synthesis and associates with atopic asthma. Nat Genet. 1998, 19: 119-120. 10.1038/472.PubMed

S86.

Noguchi E, Shibasaki M, Arinami T, Takeda K, Yokouchi Y, Kobayashi K, Imoto N, Nakahara S, Matsui A, Hamaguchi H: No association between atopy/asthma and the ILe50Val polymorphism of IL-4 receptor. Am J Respir Crit Care Med. 1999, 160: 342-345.PubMed

Titel: Interactions between genes and environmental factors in asthma and atopy: new developments
verfasst von: Claudia Sengler
Susanne Lau
Ulrich Wahn
Renate Nickel
Publikationsdatum: 01.12.2001
Verlag: BioMed Central
Erschienen in: Respiratory Research / Ausgabe 1/2002
Elektronische ISSN: 1465-993X
DOI: https://doi.org/10.1186/rr179

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Herzinfarkt mit 85 – trotzdem noch intensive Lipidsenkung?

16.05.2024 Hypercholesterinämie Nachrichten

Profitieren nach einem akuten Myokardinfarkt auch Betroffene über 80 Jahre noch von einer intensiven Lipidsenkung zur Sekundärprävention? Um diese Frage zu beantworten, wurden jetzt Registerdaten aus Frankreich ausgewertet.

CKD bei Diabetes: Neuheiten und Zukunftsaussichten

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Jeder Mensch mit Diabetes muss auf eine chronische Nierenerkrankung gescreent werden – diese neue Empfehlung spricht die KDIGO aus. Die Therapie erfolgt individuell und je nach Szenario mit verschiedenen Substanzklassen. Künftig kommt wahrscheinlich, neben RAS-Hemmung, SGLT2-Inhibition und nsMRA, eine vierte Therapiesäule hinzu.

Riesenzellarteriitis: 15% der Patienten sind von okkulter Form betroffen

16.05.2024 Riesenzellarteriitis Nachrichten

In einer retrospektiven Untersuchung haben Forschende aus Belgien und den Niederlanden die okkulte Form der Riesenzellarteriitis genauer unter die Lupe genommen. In puncto Therapie und Rezidivraten stellten sie keinen sehr großen Unterschied zu Erkrankten mit kranialen Symptomen fest.

SGLT2-Inhibitoren und GLP-1-Rezeptoragonisten im Schlagabtausch

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Wer hat die Nase vorn – SGLT2-Inhibitoren oder GLP-1-Rezeptoragonisten? Diese Frage diskutierten zwei Experten in einer Session auf dem diesjährigen Diabetes-Kongress.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen